Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stroke prevention in atrial fibrillation.

R G Hart1

  • 1Department of Medicine (Neurology), University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78284-7883, USA. Hartr@UTHSCSA.edu.

Current Cardiology Reports
|September 12, 2000
PubMed
Summary

Nonvalvular atrial fibrillation (AF) increases stroke risk. Warfarin is recommended for high-risk patients, while aspirin suits low-risk individuals or those unable to take warfarin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial.

European journal of neurology·2020
Same author

Novel oral anticoagulants in secondary prevention of stroke.

Best practice & research. Clinical haematology·2013
Same author

Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.

Lancet (London, England)·2013
Same author

Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Albuminuria and the risk of incident stroke and stroke types in older adults.

Neurology·2010
Same author

Relationship therapy in a children's psychiatric ward; case report.

The American journal of psychiatry·2010

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Nonvalvular atrial fibrillation (AF) is a significant independent risk factor for ischemic stroke.
  • Stroke risk in AF patients without prior stroke averages 5% annually, influenced by thromboembolic risk factors.
  • Existing risk stratification schemes for AF stroke risk require further validation in clinical practice.

Purpose of the Study:

  • To review the efficacy and safety of antithrombotic therapies for stroke prevention in nonvalvular atrial fibrillation.
  • To guide the selection of appropriate antithrombotic therapy based on individual stroke and bleeding risk.

Main Methods:

  • Review of existing literature on stroke risk in AF and the effectiveness of warfarin and aspirin.
  • Analysis of stroke risk stratification schemes and their clinical applicability.
  • Consideration of patient-specific factors, including bleeding risk and preferences.

Main Results:

  • Adjusted-dose warfarin (INR 2-3) reduces stroke by approximately 60% in AF patients and is relatively safe with monitoring.
  • Aspirin provides a modest stroke reduction (approximately 20%) but is less effective than warfarin.
  • The role of transesophageal echocardiography in routine AF management remains undetermined.

Conclusions:

  • Warfarin therapy is recommended for high-risk AF patients who can safely undergo monitoring.
  • Aspirin may be suitable for low-risk AF patients or those who cannot tolerate warfarin.
  • For moderate-risk patients, antithrombotic therapy decisions should balance bleeding risks with patient preferences.

Related Experiment Videos